Drugs in R & D

, Volume 4, Issue 2, pp 113–114 | Cite as

Alpha-Antitrypsin — Alpha Therapeutic Corporation

AAT — Alpha Therapeutic Corporation, Alpha-1 Proteinase Inhibitor — Alpha Therapeutic Corporation, Alpha-1-Antitrypsin — Alpha Therapeutic Corporation, Aralast™, Respitin™
Adis R&D Profile


Airflow Obstruction Bioequivalence Study Antitrypsin Deficiency Profile Therapeutics Initial Treatment Period 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Baxter Healthcare Corporation. Baxter to Acquire Alpha-1 Antitrypsin and Other Assets From Alpha Therapeutic Corporation. Media Release: 20 Dec 2002. Available from URL: Google Scholar
  2. 2.
    Alpha Therapeutic Corporation. Alpha Therapeutic Corporation Announces Development Agreement for New Inhaled Therapy for Genetic Emphysema Media Release: 1 Aug 2002. Available from URL:
  3. 3.
    Alpha Therapeutic Corporation, Baxter Healthcare Corporation. Alpha Therapeutic Corporation Receives FDA Approval for Aralast™ Alpha-1 Proteinase Inhibitor. Media Release: 9 Jan 2003. Available from URL: Google Scholar
  4. 4.
    Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha-1-antitrypsin, Respitin. Chest. 122: 66–74, Jul 2002PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Personalised recommendations